['arthritis, rheumatoid']
['abp 798', 'rituximab (us)', 'rituximab (eu)']

        Inclusion Criteria:

          -  Men or women ≥ 18 and ≤ 80 years old

          -  Subjects must be diagnosed with rheumatoid arthritis for at least 6 months before
             baseline

          -  Active RA defined as ≥ 6 swollen joints and ≥ 6 tender joints at screening and
             baseline and at least one of the following at screening:

               -  erythrocyte sedimentation rate (ESR) ≥ 28 mm/hr

               -  serum C-reactive protein (CRP) > 1.0 mg/dL

          -  Subjects must be taking methotrexate (MTX) for ≥ 12 consecutive weeks and on a stable
             dose of MTX 7.5 to 25 mg/week for ≥ 8 weeks prior to receiving the investigational
             product (IP), and be willing to remain on a stable dose throughout the study

          -  Subject has no known history of active tuberculosis

        Exclusion Criteria:

          -  Class IV RA, Felty's syndrome or history of prosthetic or native joint infection

          -  Major chronic inflammatory disease or connective tissue disease other than RA, with
             the exception of secondary Sjögren's syndrome

          -  Use of commercially available or investigational biologic therapies for RA as follows:

               -  anakinra, etanercept within 1 month prior to first dose of IP

               -  infliximab, abatacept, tocilizumab, golimumab, certolizumab within 3 months prior
                  to first dose of IP

               -  other experimental or commercially available biologic therapies for RA within 3
                  months or 5 half-lives (whichever is longer) prior to first dose of IP

          -  Previous receipt of rituximab or a biosimilar of rituximab

        Other Inclusion/Exclusion criteria may apply
      